Author

Jeff McLeroy

Observed name: J. McLeroy

Institution: Allogene Therapeutics (United States)

Observed institutions: University of California, San Francisco, Allogene Therapeutics (United States), Stanford Medicine, Kite (United States), Stanford University

OpenAlex ID: A5029620109

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

2021 · Olalekan O. Oluwole, Krimo Bouabdallah, et al. · British Journal of Haematology · 218

Gastric acid secretion in aquaporin-4 knockout mice

2000 · Kasper S. Wang, Alex R. Komar, et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 69

Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

2021 · Olalekan O. Oluwole, Krimo Bouabdallah, et al. · Transplantation and Cellular Therapy · 7

Decreased gastric acid production in aquaporin 4 knockout mice

1998 · A.R. Komar, T. Ma, et al. · Gastroenterology · 2

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

2026 · Samer A. Srour, Jad Chahoud, et al. · Journal of Clinical Oncology · 1

Works count: 5

Citation count: 297

H-index: 3

I10-index: 2